Texas Permanent School Fund Vertex Pharmaceuticals Inc Transaction History

Texas Permanent School Fund

$597 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$392.81 - $485.53 $4.11 Million - $5.08 Million	-10,473 Reduced 19.65%	42,815 $20.1 Million
Q1 2024 May 03, 2024	BUY	$407.69 - $446.08 $26,499 - $28,995	65 Added 0.12%	53,288 $22.3 Million
Q4 2023 Feb 08, 2024	SELL	$343.0 - $410.68 $42,875 - $51,335	-125 Reduced 0.23%	53,223 $21.7 Million
Q3 2023 Nov 09, 2023	SELL	$338.18 - $362.46 $228,947 - $245,385	-677 Reduced 1.25%	53,348 $18.6 Million
Q2 2023 Aug 07, 2023	BUY	$314.42 - $351.91 $133,942 - $149,913	426 Added 0.79%	54,025 $19 Million
Q1 2023 May 01, 2023	BUY	$283.23 - $323.1 $4.85 Million - $5.53 Million	17,128 Added 46.96%	53,599 $16.9 Million
Q4 2022 Feb 07, 2023	BUY	$285.76 - $321.48 $52,579 - $59,152	184 Added 0.51%	36,471 $10.5 Million
Q3 2022 Oct 25, 2022	BUY	$273.83 - $305.53 $686,217 - $765,658	2,506 Added 7.42%	36,287 $10.5 Million
Q2 2022 Aug 08, 2022	BUY	$234.96 - $292.55 $178,569 - $222,338	760 Added 2.3%	33,781 $9.52 Million
Q1 2022 May 06, 2022	SELL	$221.42 - $260.97 $442,175 - $521,157	-1,997 Reduced 5.7%	33,021 $8.62 Million
Q4 2021 Feb 08, 2022	SELL	$177.01 - $223.45 $895,670 - $1.13 Million	-5,060 Reduced 12.63%	35,018 $7.69 Million
Q3 2021 Oct 28, 2021	SELL	$181.39 - $202.99 $530,928 - $594,151	-2,927 Reduced 6.81%	40,078 $7.27 Million
Q2 2021 Jul 27, 2021	SELL	$187.49 - $221.1 $75,745 - $89,324	-404 Reduced 0.93%	43,005 $8.67 Million
Q1 2021 May 03, 2021	SELL	$207.02 - $241.31 $504,714 - $588,313	-2,438 Reduced 5.32%	43,409 $9.33 Million
Q4 2020 Feb 04, 2021	SELL	$207.01 - $276.09 $645,457 - $860,848	-3,118 Reduced 6.37%	45,847 $10.8 Million
Q3 2020 Nov 06, 2020	BUY	$255.65 - $303.1 $837,765 - $993,258	3,277 Added 7.17%	48,965 $13.3 Million
Q2 2020 Aug 04, 2020	SELL	$225.48 - $295.8 $227,960 - $299,053	-1,011 Reduced 2.16%	45,688 $13.3 Million
Q1 2020 Apr 27, 2020	BUY	$199.77 - $247.81 $239,124 - $296,628	1,197 Added 2.63%	46,699 $11.1 Million
Q4 2019 Feb 03, 2020	SELL	$166.71 - $223.91 $396,269 - $532,234	-2,377 Reduced 4.96%	45,502 $9.96 Million
Q3 2019 Oct 31, 2019	SELL	$166.23 - $187.09 $251,672 - $283,254	-1,514 Reduced 3.07%	47,879 $8.11 Million
Q2 2019 Aug 09, 2019	SELL	$164.61 - $190.37 $56,461 - $65,296	-343 Reduced 0.69%	49,393 $9.06 Million
Q1 2019 May 02, 2019	SELL	$163.73 - $194.7 $272,774 - $324,370	-1,666 Reduced 3.24%	49,736 $9.15 Million
Q4 2018 Feb 11, 2019	SELL	$151.91 - $192.21 $906,598 - $1.15 Million	-5,968 Reduced 10.4%	51,402 $8.52 Million
Q3 2018 Oct 22, 2018	SELL	$167.73 - $192.74 $807,787 - $928,235	-4,816 Reduced 7.74%	57,370 $11.1 Million
Q2 2018 Jul 23, 2018	SELL	$145.72 - $169.96 $497,633 - $580,413	-3,415 Reduced 5.21%	62,186 $10.6 Million
Q1 2018 Apr 20, 2018	SELL	$151.6 - $177.13 $521,504 - $609,327	-3,440 Reduced 4.98%	65,601 $10.7 Million
Q4 2017 Jan 23, 2018	SELL	$137.28 - $155.55 $113,805 - $128,950	-829 Reduced 1.19%	69,041 $10.3 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $10.3 Million - $11.3 Million	69,870	69,870 $10.6 Million

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$12.1 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$10.4 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$9.61 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$5.33 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$4.06 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Texas Permanent School Fund, based on Form 13F filings with the SEC.

News

Stay updated on Texas Permanent School Fund with notifications on news.

Account